Intravenous magnesium sulfate for acute wheezing in young children: a randomised double-blind trial

Area of Science:

• Pediatrics
• Pulmonology
• Pharmacology

Background:

• Magnesium sulfate is effective for asthma exacerbations in older children.
• Its efficacy in acute severe virus-induced wheezing in young children remains uninvestigated.

Purpose of the Study:

• To evaluate the effectiveness of intravenous magnesium sulfate in treating acute severe virus-induced wheezing in young children.
• To compare magnesium sulfate treatment against a placebo in this specific pediatric population.

Main Methods:

• A randomized controlled trial involving 61 children aged 6 months to 4 years with severe wheezing (RDAI score ≥6) and acute viral infection.
• Participants received either magnesium sulfate (40 mg·kg⁻¹) or a saline placebo infusion over 20 minutes.
• The primary outcome was the mean change in Respiratory Distress Assessment Instrument (RDAI) scores from baseline to 6 hours post-treatment.

Main Results:

• The mean change in RDAI scores at 6 hours was 4.7±2.6 in the magnesium sulfate group and 4.2±4.2 in the placebo group.
• The difference in RDAI score change between groups was not statistically significant (difference 0.5, 95% CI -1.3 to 2.3, p=0.594).

Conclusions:

• Intravenous magnesium sulfate was ineffective in treating acute severe virus-induced wheezing in young children.
• Findings contrast with established efficacy in older children, suggesting age-specific treatment responses for wheezing exacerbations.